CA2840571C - High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis - Google Patents

High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis Download PDF

Info

Publication number
CA2840571C
CA2840571C CA2840571A CA2840571A CA2840571C CA 2840571 C CA2840571 C CA 2840571C CA 2840571 A CA2840571 A CA 2840571A CA 2840571 A CA2840571 A CA 2840571A CA 2840571 C CA2840571 C CA 2840571C
Authority
CA
Canada
Prior art keywords
mtz
gel
gel composition
weight
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2840571A
Other languages
English (en)
French (fr)
Other versions
CA2840571A1 (en
Inventor
Michael T. Nordsiek
Kodumudi S. Balaji
Original Assignee
Chemo Research SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47391265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2840571(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Research SL filed Critical Chemo Research SL
Priority to CA3054236A priority Critical patent/CA3054236A1/en
Publication of CA2840571A1 publication Critical patent/CA2840571A1/en
Application granted granted Critical
Publication of CA2840571C publication Critical patent/CA2840571C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2840571A 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis Active CA2840571C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3054236A CA3054236A1 (en) 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161502285P 2011-06-28 2011-06-28
US61/502,285 2011-06-28
US201161508058P 2011-07-14 2011-07-14
US61/508,058 2011-07-14
PCT/US2012/044738 WO2013003646A1 (en) 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3054236A Division CA3054236A1 (en) 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis

Publications (2)

Publication Number Publication Date
CA2840571A1 CA2840571A1 (en) 2013-01-03
CA2840571C true CA2840571C (en) 2020-03-24

Family

ID=47391265

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2840571A Active CA2840571C (en) 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
CA3054236A Abandoned CA3054236A1 (en) 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3054236A Abandoned CA3054236A1 (en) 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis

Country Status (9)

Country Link
US (4) US8946276B2 (https=)
EP (1) EP2725904B1 (https=)
JP (2) JP5986632B2 (https=)
CN (2) CN107823123A (https=)
AU (2) AU2012275292B2 (https=)
BR (1) BR112013033759B1 (https=)
CA (2) CA2840571C (https=)
MX (1) MX381271B (https=)
WO (1) WO2013003646A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201590008A1 (ru) 2012-06-13 2015-05-29 Ивофем, Инк. Композиции и способы повышения эффективности бактерицидных средств контрацепции
US9446024B2 (en) 2013-06-25 2016-09-20 UNIVERSITé LAVAL Formulations for the treatment of vaginal disorders
JP2017501227A (ja) 2013-12-19 2017-01-12 エヴォフェム，インク． アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
KR20170052626A (ko) * 2014-09-05 2017-05-12 심바이오믹스 세러퓨틱스 엘엘씨 세균질증 치료에 사용하기 위한 세크니다졸
CA2988082C (en) 2015-06-01 2020-09-29 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
US10759740B2 (en) 2016-03-24 2020-09-01 Rutgers, The State University Of New Jersey Antibacterial agents
US11419835B2 (en) 2016-10-04 2022-08-23 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis
SE1750680A1 (en) * 2017-05-30 2018-12-01 Peptonic Medical Ab Composition for treating or preventing climacteric disorders
US20200126094A1 (en) * 2018-10-19 2020-04-23 BioIDC, Inc. Medical research fraud detection system and software
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
WO1988006888A1 (en) 1987-03-20 1988-09-22 Curatek Pharmaceuticals, Inc. Novel topical metronidazole formulations and therapeutic uses thereof
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
EP0537784B1 (en) 1991-10-18 1995-03-01 Dow Corning Corporation Silicone pressure sensitive adhesives having enhanced adhesion to low energy substrates
IT1284874B1 (it) * 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
GB9626513D0 (en) 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
WO1998014768A2 (en) 1997-10-06 1998-04-09 Schwartz Sorell L Transdermal chemical monitoring device
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
US7368122B1 (en) 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US20050186142A1 (en) 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7456207B2 (en) * 2003-09-25 2008-11-25 Teva Pharmaceuticals Usa, Inc. Vaginal pharmaceutical compositions and methods for preparing them
FR2887149B1 (fr) 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
FR2882552B1 (fr) 2005-02-25 2008-12-26 Galderma Sa Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation
AU2006298442A1 (en) 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
CA2611577A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
FR2890559B1 (fr) 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour la preparation
FR2890560B1 (fr) 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation
BRPI0617693A2 (pt) 2005-11-09 2011-08-02 Dow Pharmaceutical Sciences azitromicina para o tratamento de rosácea granulomatosa
CN101374501A (zh) 2006-01-05 2009-02-25 药物技术公司 组合物及其使用方法
FR2899475A1 (fr) 2006-04-10 2007-10-12 Galderma Res & Dev Composition pharmaceutique pour le traitement de la rosacee
EP2029106A2 (en) 2006-06-07 2009-03-04 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
US20080287515A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287514A1 (en) 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287513A1 (en) 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080312304A1 (en) 2007-06-13 2008-12-18 Jerry Zhang Topical compositions containing metronidazole
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20100105750A1 (en) 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
CA2790682C (en) 2010-03-03 2020-11-24 Neocutis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds

Also Published As

Publication number Publication date
CN103763925A (zh) 2014-04-30
US10596155B2 (en) 2020-03-24
US10238634B2 (en) 2019-03-26
CN107823123A (zh) 2018-03-23
EP2725904A1 (en) 2014-05-07
AU2016200825B2 (en) 2017-10-26
US20130005787A1 (en) 2013-01-03
BR112013033759A8 (pt) 2018-07-31
WO2013003646A1 (en) 2013-01-03
CA3054236A1 (en) 2013-01-03
JP2014518272A (ja) 2014-07-28
US8946276B2 (en) 2015-02-03
EP2725904A4 (en) 2014-12-10
CA2840571A1 (en) 2013-01-03
MX2014000066A (es) 2014-05-01
BR112013033759A2 (pt) 2016-08-16
AU2012275292A1 (en) 2014-01-23
EP2725904B1 (en) 2024-12-11
JP2017014248A (ja) 2017-01-19
US9198858B2 (en) 2015-12-01
MX381271B (es) 2025-03-11
BR112013033759B1 (pt) 2021-05-25
US20130005785A1 (en) 2013-01-03
AU2012275292B2 (en) 2015-11-12
AU2016200825A1 (en) 2016-03-03
JP5986632B2 (ja) 2016-09-06
US20190183859A1 (en) 2019-06-20
JP6235087B2 (ja) 2017-11-22
US20160106714A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
US10596155B2 (en) Aqueous-based metronidazole gel formulations
RU2632110C2 (ru) Способ лечения или профилактики бактериального вагиноза
AU2013292179B2 (en) Pharmaceutical compositions containing oligomeric lactic acid
US7456207B2 (en) Vaginal pharmaceutical compositions and methods for preparing them
US20060105008A1 (en) Compositions and methods for reducing vaginal pH
US20060172007A1 (en) Compositions and methods for reducing vaginal pH
JP2007077150A (ja) 酸−酸緩衝系を含有する無水組成物
US20140206735A1 (en) High dosage topical metronidazole aqueous-based gel formulations and their use to treat rosacea
US20250268934A1 (en) Compositions and Methods for the Treatment of Bacterial Vaginosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170627

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620